Sarah A Twichell1, Elizabeth A K Hunt2, Karen Martz3, Michael J G Somers4,5. 1. Department of Pediatrics, Robert Larner, M.D. College of Medicine and the University of Vermont Children's Hospital, The University of Vermont, Burlington, VT, USA. sarah.twichell@uvmhealth.org. 2. Department of Pediatrics, Robert Larner, M.D. College of Medicine and the University of Vermont Children's Hospital, The University of Vermont, Burlington, VT, USA. 3. EMMES Corporation, Rockville, MD, USA. 4. Division of Nephrology, Boston Children's Hospital, Boston, MA, USA. 5. Department of Pediatrics, Harvard Medical School, Boston, MA, USA.
Abstract
BACKGROUND: While adult hemodialysis (HD) patients have increased morbidity with higher target hemoglobin levels, similar findings have not been demonstrated in pediatric patients. We evaluated changes in transfusions, anemia frequency, and erythropoietin (epo) dosing among pediatric HD patients before, during, and after implementation of federal dialysis payment policies regarding epo dosing for adult HD patients. METHODS: This is a retrospective cohort study of pediatric HD patients enrolled in NAPRTCS. We evaluated need for transfusion, anemia, median hemoglobin, and median epo dose 6 months after starting HD in 3 eras: baseline (2003-2007), implementation (2008-2011), and post implementation (2012-2016). We used multivariate logistic regression models to evaluate potential differences in transfusion across the eras. RESULTS: Six months after dialysis initiation, 12.6% of patients required transfusion pre-implementation, 17.9% during implementation, and 15.5% post implementation. Anemia occurred in 17.4% of patients pre, 23.5% during, and 23.8% post implementation, with median hemoglobin levels of 11.9 g/dL pre, 11 g/dL during, and 11 g/dL post implementation. Epo use was high across all 3 eras, but epo dosing decreased during and post implementation, despite more anemia during these periods. Odds of transfusion in implementation era compared with pre-implementation was 1.75 (95% CI 1.11-2.77) and odds of transfusion in post implementation era compared with pre was 1.19 (95% CI 0.71-1.98), controlling for age, race, gender, and prior transplant status. CONCLUSIONS: During and following implementation of adult epo dosing guidelines, transfusion and anemia frequency increased in pediatric HD patients. Ideal target hemoglobin levels for pediatric dialysis patients warrant further study.
BACKGROUND: While adult hemodialysis (HD) patients have increased morbidity with higher target hemoglobin levels, similar findings have not been demonstrated in pediatric patients. We evaluated changes in transfusions, anemia frequency, and erythropoietin (epo) dosing among pediatric HDpatients before, during, and after implementation of federal dialysis payment policies regarding epo dosing for adult HDpatients. METHODS: This is a retrospective cohort study of pediatric HDpatients enrolled in NAPRTCS. We evaluated need for transfusion, anemia, median hemoglobin, and median epo dose 6 months after starting HD in 3 eras: baseline (2003-2007), implementation (2008-2011), and post implementation (2012-2016). We used multivariate logistic regression models to evaluate potential differences in transfusion across the eras. RESULTS: Six months after dialysis initiation, 12.6% of patients required transfusion pre-implementation, 17.9% during implementation, and 15.5% post implementation. Anemia occurred in 17.4% of patients pre, 23.5% during, and 23.8% post implementation, with median hemoglobin levels of 11.9 g/dL pre, 11 g/dL during, and 11 g/dL post implementation. Epo use was high across all 3 eras, but epo dosing decreased during and post implementation, despite more anemia during these periods. Odds of transfusion in implementation era compared with pre-implementation was 1.75 (95% CI 1.11-2.77) and odds of transfusion in post implementation era compared with pre was 1.19 (95% CI 0.71-1.98), controlling for age, race, gender, and prior transplant status. CONCLUSIONS: During and following implementation of adult epo dosing guidelines, transfusion and anemia frequency increased in pediatric HDpatients. Ideal target hemoglobin levels for pediatric dialysis patients warrant further study.
Authors: Julie M Yabu; Matthew W Anderson; Deborah Kim; Brian D Bradbury; Calvin D Lou; Jeffrey Petersen; Jerome Rossert; Glenn M Chertow; Dolly B Tyan Journal: Nephrol Dial Transplant Date: 2013-09-05 Impact factor: 5.992
Authors: G Montini; G Zacchello; E Baraldi; S Zanconato; A Suppiej; F Fabris; B Andreetta; L Pavanello; F Zacchello Journal: J Pediatr Date: 1990-10 Impact factor: 4.406
Authors: Amy O Staples; Craig S Wong; Jodi M Smith; Debbie S Gipson; Guido Filler; Bradley A Warady; Karen Martz; Larry A Greenbaum Journal: Clin J Am Soc Nephrol Date: 2008-12-03 Impact factor: 8.237
Authors: Dagmara Borzych-Duzalka; Yelda Bilginer; Il Soo Ha; Mustafa Bak; Lesley Rees; Francisco Cano; Reyner Loza Munarriz; Annabelle Chua; Silvia Pesle; Sevinc Emre; Agnieszka Urzykowska; Lily Quiroz; Javier Darío Ruscasso; Colin White; Lars Pape; Virginia Ramela; Nikoleta Printza; Andrea Vogel; Dafina Kuzmanovska; Eva Simkova; Dirk E Müller-Wiefel; Anja Sander; Bradley A Warady; Franz Schaefer Journal: J Am Soc Nephrol Date: 2013-03-07 Impact factor: 10.121
Authors: Juan C Scornik; Jonathan S Bromberg; Douglas J Norman; Mayank Bhanderi; Matthew Gitlin; Jeffrey Petersen Journal: BMC Nephrol Date: 2013-10-10 Impact factor: 2.388